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background: β-blocker (BB) therapy is recommended to decrease cardiac adverse events after acute myocardial infarction (AMI). This 
study aimed to investigate the impact of BB therapy on long-term outcomes in patients with AMI and multivessel coronary disease (MCD) 
following percutaneous coronary intervention (PCI).
methods:  To compare the impact of BB therapy on long-term outcomes, we excluded patients died in hospital considering their low 
proportion of receiving the therapy. A total of 925 patients (Male 706) undergoing primary PCI for AMI were classified into 4 groups 
according to MCD and/or BB therapy at discharge (with MCD/without BB n=173, with MCD/with BB n=220, without MCD/without BB n=220, 
without MCD/with BB n=312). The endpoint was all-cause mortality.
Results:  Patients with MCD had significantly higher proportion of all-cause mortality than patients without MCD, and in the presence or 
absence of MCD, patients without BB therapy tended to have a higher proportion of all-cause mortality. Importantly, absence of BB therapy 
significantly worsened event-free survival in patients with MCD (P=0.007, by the log-rank test), whereas it did not in those without MCD. 
Moreover, according to a multivariate analysis, BB therapy was found to be an independent predictor of all-cause mortality in patients with 
MCD (HR:0.41, 95%CI:0.17-0.95, P=0.038).
conclusion:  In the presence of MCD, the implementation of BB therapy was associated with better long-term outcomes in AMI patients.
 
